Filarial Elephantiasis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Filarial Elephantiasis

MalaCards integrated aliases for Filarial Elephantiasis:

Name: Filarial Elephantiasis 12 52 15 17
Lymphatic Filariasis 12 74 52 58 54 3 15
Elephantiasis 52 71
Filariasis 52 71
Infection by Wuchereria Bancrofti 71
Wuchereria Bancrofti Infection 52
Bancroftian Filarial Chyluria 12
Malayi Tropical Eosinphilia 52
Bancroftian Elephantiasis 12
Elephantiasis of Eyelid 12
Elephantiasis, Filarial 43
Bancroftian Filariasis 52
Filarial Elephantiases 71
Wuchereriasis 52
Elephantitis 52


Orphanet epidemiological data:

lymphatic filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;


Orphanet: 58  
Rare infectious diseases

External Ids:

Disease Ontology 12 DOID:12211
MeSH 43 D004605
NCIt 49 C128360
SNOMED-CT 67 240820001
ICD10 via Orphanet 33 B74.0 B74.1 B74.2
UMLS via Orphanet 72 C0013884
Orphanet 58 ORPHA2035
UMLS 71 C0013882 C0013884 C0016085 more

Summaries for Filarial Elephantiasis

NIH Rare Diseases : 52 Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms that only live in the human lymph system , which maintains the body's fluid balance and fights infections. It is spread from person to person by mosquitoes. Most infected people are asymptomatic and never develop clinical symptoms. A small percentage of people develop lymphedema , which may affect the legs, arms, breasts, and genitalia; bacterial infections that cause hardening and thickening of the skin, called elephantiasis; hydrocele (swelling of the scrotum) in men; and pulmonary tropical eosinophilia syndrome . Treatment may include a yearly dose of medicine, called diethylcarbamazine (DEC); while this drug does not kill all of the adult worms, it prevents infected people from giving the disease to someone else.

MalaCards based summary : Filarial Elephantiasis, also known as lymphatic filariasis, is related to podoconiosis and loiasis, and has symptoms including chyluria An important gene associated with Filarial Elephantiasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Akt Signaling and Allograft rejection. The drugs Doxycycline and Antimalarials have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and testes, and related phenotypes are proteinuria and fatigue

Disease Ontology : 12 A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.

CDC : 3 Lymphatic filariasis, considered globally as a neglected tropical disease (NTD), is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes. People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.

Wikipedia : 74 Lymphatic filariasis is a human disease caused by parasitic worms known as filarial worms. Most cases of... more...

Related Diseases for Filarial Elephantiasis

Diseases related to Filarial Elephantiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 585)
# Related Disease Score Top Affiliating Genes
1 podoconiosis 32.8 STH CNTD1
2 loiasis 32.6 STH SRCIN1 IL5 IL4 IL13 IL10
3 onchocerciasis 32.4 STH SRCIN1 IL5 IL4 IL13 CNTD1
4 hypereosinophilic syndrome 31.4 IL5 IL4 IL13 IL10
5 schistosomiasis 31.2 IL5 IL4 IL13 IL10
6 eosinophilic pneumonia 31.2 IL5 IL4 IL13
7 pulmonary eosinophilia 31.2 IL5 IL4 IL13
8 lymphadenitis 31.0 TLR4 IL10 CD4
9 cytokine deficiency 31.0 IL5 IL13
10 orchitis 31.0 IL4 IL10 CD4
11 elephantiasis 30.9 STH SRCIN1 IL5 IL4 IL13 IL10
12 endomyocardial fibrosis 30.9 IL5 IL4 IL10
13 filariasis 30.8 TLR4 TLR2 IL5 IL10
14 toxocariasis 30.6 IL5 IL4 IL10 EPGN
15 ascaris lumbricoides infection 30.6 STH IL5 IL13 IL10 EPGN
16 dracunculiasis 30.5 STH MPG EPGN ADIRF
17 cellulitis 30.5 IL5 IL4 IL10 CD4
18 strongyloidiasis 30.5 STH IL5 IL13 EPGN CD4
19 poliomyelitis 30.5 IL4 IL10 CD4
20 bacterial infectious disease 30.4 TLR4 TLR2 IL10 CD4
21 cysticercosis 30.4 TLR4 STH IL10 CD4
22 dermatitis 30.4 IL5 IL4 IL13 IL10
23 trachoma 30.4 STH MPG IL4 IL10
24 trypanosomiasis 30.4 TLR4 TLR2 IL4 IL10
25 silicosis 30.3 TLR4 IL4 IL10
26 trichuriasis 30.3 STH IL13 IL10 EPGN
27 panuveitis 30.3 LCOR IL10 CD4
28 allergic hypersensitivity disease 30.3 IL5 IL4 IL13 IL10 CD4
29 yaws 30.3 STH MPG ADIRF
30 ige responsiveness, atopic 30.2 IL5 IL4 IL13 IL10
31 urticaria 30.2 IL5 IL4 IL13 IL10
32 meningoencephalitis 30.2 IL4 IL10 CD4
33 b cell deficiency 30.2 IL4 IL10 CD4
34 echinococcosis 30.2 TLR4 TLR2 IL5 IL10
35 systemic scleroderma 30.2 IL4 IL13 IL10 CD4
36 tetanus 30.2 IL5 IL4 IL13 IL10
37 severe combined immunodeficiency 30.2 IL5 IL4 IL13 IL10 CD4
38 keratoconjunctivitis 30.2 IL5 IL4 IL13
39 angiostrongyliasis 30.1 IL5 IL4 IL13
40 cystic echinococcosis 30.1 TLR4 TLR2 IL10
41 dengue hemorrhagic fever 30.1 IL4 IL13 IL10
42 posterior uveitis 30.1 IL5 IL4 IL13
43 paragonimiasis 30.1 STH IL5 IL13 EPGN
44 leishmaniasis 30.1 TLR4 TLR2 IL5 IL4 IL13 IL10
45 lepromatous leprosy 30.0 TLR2 IL4 IL10
46 rheumatic heart disease 30.0 TLR2 IL4 IL10
47 trichinosis 30.0 IL5 IL4 IL13 IL10 CD4
48 taeniasis 30.0 TLR4 STH IL4 IL10 CD4
49 lichen planus 29.9 TLR2 IL4 IL10
50 plague 29.9 TLR4 TLR2 IL10 CD4

Graphical network of the top 20 diseases related to Filarial Elephantiasis:

Diseases related to Filarial Elephantiasis

Symptoms & Phenotypes for Filarial Elephantiasis

Human phenotypes related to Filarial Elephantiasis:

58 (show all 33)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 proteinuria 58 Very rare (<4-1%)
2 fatigue 58 Frequent (79-30%)
3 fever 58 Occasional (29-5%)
4 hyperkeratosis 58 Frequent (79-30%)
5 lymphedema 58 Very frequent (99-80%)
6 hematuria 58 Very rare (<4-1%)
7 cough 58 Occasional (29-5%)
8 nephrotic syndrome 58 Very rare (<4-1%)
9 abnormality of the lymphatic system 58 Very frequent (99-80%)
10 abnormality of the kidney 58 Occasional (29-5%)
11 abnormal lung morphology 58 Occasional (29-5%)
12 lymphadenopathy 58 Very frequent (99-80%)
13 abnormality of the scrotum 58 Occasional (29-5%)
14 restrictive deficit on pulmonary function testing 58 Occasional (29-5%)
15 orchitis 58 Occasional (29-5%)
16 vaginal hydrocele 58 Occasional (29-5%)
17 urethral obstruction 58 Very rare (<4-1%)
18 hyperpigmentation of the skin 58 Frequent (79-30%)
19 predominantly lower limb lymphedema 58 Very frequent (99-80%)
20 pain 58 Frequent (79-30%)
21 hydrocele testis 58 Occasional (29-5%)
22 glomerulonephritis 58 Very rare (<4-1%)
23 circulating immune complexes 58 Frequent (79-30%)
24 hypereosinophilia 58 Frequent (79-30%)
25 ankle swelling 58 Very rare (<4-1%)
26 no social interaction 58 Very rare (<4-1%)
27 wheezing 58 Occasional (29-5%)
28 lymphadenitis 58 Frequent (79-30%)
29 knee osteoarthritis 58 Very rare (<4-1%)
30 opportunistic infection 58 Occasional (29-5%)
31 lymphangiectasis 58 Occasional (29-5%)
32 opportunistic bacterial infection 58 Occasional (29-5%)
33 epididymitis 58 Very rare (<4-1%)

UMLS symptoms related to Filarial Elephantiasis:


MGI Mouse Phenotypes related to Filarial Elephantiasis:

# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 CD4 FUZ IL10 IL13 IL4 IL5
2 endocrine/exocrine gland MP:0005379 9.28 CD4 CNTD1 EPGN FUZ IL10 IL13

Drugs & Therapeutics for Filarial Elephantiasis

Drugs for Filarial Elephantiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
2 Antimalarials Phase 4
Petrolatum Approved, Investigational Phase 3 8009-03-8
Glycerol Approved, Investigational Phase 3 56-81-5 753
5 Eusol Phase 3
6 Protective Agents Phase 3
7 Sodium hypochlorite Phase 3
8 Vitamins Phase 3
9 Milbemycin Phase 3
Reslizumab Approved, Investigational Phase 2 241473-69-8
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 2 90-89-1 3052
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
14 Respiratory System Agents Phase 2
15 Immunoglobulins Phase 2
16 Antibodies Phase 2
17 Anti-Asthmatic Agents Phase 2
18 Antibodies, Monoclonal Phase 2
19 Protein Kinase Inhibitors Phase 2
20 Imatinib Mesylate Phase 2 220127-57-1 123596
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
23 Pharmaceutical Solutions Phase 1
24 Toltrazuril Phase 1
Polidocanol Approved 9002-92-0
Sodium citrate Approved, Investigational 68-04-2
Mebendazole Approved, Vet_approved 31431-39-7 4030
Piperazine Approved, Vet_approved 110-85-0 4837
Permethrin Approved, Investigational 52645-53-1 40326
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
31 Anesthetics
32 Sclerosing Solutions
33 Citrate
34 Piperazine citrate
35 DMP 777 157341-41-8
36 Liver Extracts
37 Insect Repellents

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
3 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
4 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
5 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
6 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
7 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
8 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
9 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
10 A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia Completed NCT02839772 Phase 3
11 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
12 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Recruiting NCT04410406 Phase 3 IA (IVM+ ABZ);MoxA (Mox + ABZ);IDA (IVM + DEC + ABZ);MoxDA (Mox + DEC + ABZ)
13 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
14 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
15 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
16 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
17 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
18 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
19 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
20 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
21 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
22 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
23 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
24 A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
25 Study on Selective Pelvic Lymphadenectomy for IB-IIA Cervical Cancer Recruiting NCT03295526 Phase 2
26 A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19 Recruiting NCT04381884 Phase 2 IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
27 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Active, not recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
28 Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis Enrolling by invitation NCT04188301 Phase 2 IVM w/ ALB;Single dose of IDA;Three daily doses of IDA
29 Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms Not yet recruiting NCT04407507 Phase 2 Ivermectin;Placebo
30 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
31 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) or matching placebo
32 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
33 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
34 Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study. Unknown status NCT02082613
35 Prevalence of Obstructive Sleep Apnea Syndrom in Patients With Lymphedema, Admitted for Intensive Decongestive Physiotherapy Unknown status NCT02979184
36 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
37 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
38 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
39 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
40 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
41 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
42 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
43 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
44 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
45 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
46 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
47 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
48 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
49 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
50 Research for Elimination of Human Filariasis Completed NCT00145223

Search NIH Clinical Center for Filarial Elephantiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cochrane evidence based reviews: elephantiasis, filarial

Genetic Tests for Filarial Elephantiasis

Anatomical Context for Filarial Elephantiasis

MalaCards organs/tissues related to Filarial Elephantiasis:

Skin, Breast, Testes, T Cells, Lymph Node, Monocytes, Lung

Publications for Filarial Elephantiasis

Articles related to Filarial Elephantiasis:

(show top 50) (show all 2686)
# Title Authors PMID Year
Regulation of parasite antigen-driven immune responses by interleukin-10 (IL-10) and IL-12 in lymphatic filariasis. 61 54
9125556 1997
Immunoregulation in human lymphatic filariasis: the role of interleukin 10. 54 61
7501419 1995
Microfilaria in urine cytology: Report of three cases with review of literature. 61
32259405 2020
The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo. 61
32574160 2020
Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study. 61
32511226 2020
Nearly Complete Genome Sequence of Brugia malayi Strain FR3. 61
32527783 2020
Design and Analysis of Elimination Surveys for Neglected Tropical Diseases. 61
31930383 2020
Designing antifilarial drug trials using clinical trial simulators. 61
32483209 2020
Immunolocalization of Disorganized Muscle Protein-1 in Different Life Stages of Human Lymphatic Filariid, Brugia malayi. 61
32500507 2020
Genetic and functional diversification of chemosensory pathway receptors in mosquito-borne filarial nematodes. 61
32511224 2020
Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold. 61
31853554 2020
The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs. 61
31343064 2020
Eliminating Lymphatic Filariasis: Is it Worth it? 61
31343066 2020
When, Who, and How to Sample: Designing Practical Surveillance for 7 Neglected Tropical Diseases as We Approach Elimination. 61
32529261 2020
Design, expression, and evaluation of novel multiepitope chimeric antigen of Wuchereria bancrofti for the diagnosis of lymphatic filariasis - A structure-based strategy. 61
32222640 2020
An outbreak of acute skin and soft tissue infections including necrotizing fasciitis in Kalwala village, India, 2018: Public health implications for the lymphatic filariasis elimination program. 61
32562418 2020
Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis. 61
32479495 2020
Standardisation of lymphatic filariasis microfilaraemia prevalence estimates based on different diagnostic methods: a systematic review and meta-analysis. 61
32527335 2020
Post-Treatment Surveillance for Lymphatic Filariasis in Plateau and Nasarawa States, Nigeria: Results of Transmission Assessment Surveys. 61
32228796 2020
Fecundity of adult female worms were affected when Brugia malayi infected Mongolian gerbils were immunized with a multivalent vaccine (rBmHAXT) against human lymphatic filarial parasite. 61
32437645 2020
Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian crisis. 61
32479893 2020
Inhibition of Asaia in Adult Mosquitoes Causes Male-Specific Mortality and Diverse Transcriptome Changes. 61
32429180 2020
Biological effects of Avicennia marina (Forssk.) vierh. extracts on physiological, biochemical, and antimicrobial activities against three challenging mosquito vectors and microbial pathogens. 61
32072409 2020
Who Bites Me? A Tentative Discriminative Key to Diagnose Hematophagous Ectoparasites Biting Using Clinical Manifestations. 61
32429276 2020
Embryo Microinjection Techniques for Efficient Site-Specific Mutagenesis in Culex quinquefasciatus. 61
32510506 2020
Antibody response to Schistosoma haematobium and other helminth species in malaria-exposed populations from Burkina Faso. 61
32007449 2020
Development of a molecular xenomonitoring protocol to assess filariasis transmission. 61
32464220 2020
A systematic review of alternative surveillance approaches for lymphatic filariasis in low prevalence settings: Implications for post-validation settings. 61
32396575 2020
Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges. 61
32407319 2020
Significant improvement in quality of life following surgery for hydrocoele caused by lymphatic filariasis in Malawi: A prospective cohort study. 61
32384094 2020
Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania. 61
32455556 2020
The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study. 61
32469860 2020
Factors Influencing the Sustainability of Neglected Tropical Disease Elimination Programs: A Multi-Case Study of the Kenya National Program for Elimination of Lymphatic Filariasis. 61
32124717 2020
Notes from the Field: Impact of a Mass Drug Administration Campaign Using a Novel Three-Drug Regimen on Lymphatic Filariasis Antigenemia - American Samoa, 2019. 61
32463808 2020
Effect of Brugia pahangi co-infection with Plasmodium berghei ANKA in gerbils (Meriones unguiculatus). 61
32179986 2020
Exploring essential oils of Slovak medicinal plants for insecticidal activity: The case of Thymus alternans and Teucrium montanum subsp. jailae. 61
32074491 2020
Safety of high-dose ivermectin: a systematic review and meta-analysis. 61
31960060 2020
Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. 61
31948767 2020
Elucidating the possible mechanism of action of some pathogen box compounds against Leishmania donovani. 61
32275665 2020
Focus of Ongoing Onchocerciasis Transmission Close to Bangui, Central African Republic. 61
32365847 2020
Macrofilaricides: An Unmet Medical Need for Filarial Diseases. 61
32091199 2020
Investigating barriers and challenges to the integrated management of neglected tropical skin diseases in an endemic setting in Nigeria. 61
32352967 2020
Acute Lymphatic Filariasis Infection in United States Armed Forces Personnel Deployed to the Pacific Area of Operations during World War II Provides Important Lessons for Today. 61
32316470 2020
Mapping lymphatic filariasis in Loa loa endemic health districts naïve for ivermectin mass administration and situated in the forested zone of Cameroon. 61
32299374 2020
Economic benefits and costs of surgery for filarial hydrocele in Malawi. 61
32210436 2020
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial. 61
32176703 2020
The impact of leprosy, podoconiosis and lymphatic filariasis on family quality of life: A qualitative study in Northwest Ethiopia. 61
32155158 2020
The Interruption of Transmission of Human Onchocerciasis by an Annual Mass Drug Administration Program in Plateau and Nasarawa States, Nigeria. 61
32043442 2020
Quantifying the socio-economic impact of leg lymphoedema on patient caregivers in a lymphatic filariasis and podoconiosis co-endemic district of Ethiopia. 61
32126081 2020
The design and development of a multicentric protocol to investigate the impact of adjunctive doxycycline on the management of peripheral lymphoedema caused by lymphatic filariasis and podoconiosis. 61
32228663 2020

Variations for Filarial Elephantiasis

Expression for Filarial Elephantiasis

Search GEO for disease gene expression data for Filarial Elephantiasis.

Pathways for Filarial Elephantiasis

Pathways related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
Show member pathways
13.29 TLR4 TLR2 IL5 IL4 IL13 IL10
Show member pathways
12.73 IL5 IL4 IL13 IL10 CD4
Show member pathways
12.42 TLR4 TLR2 IL5 IL4 IL10 CD4
Show member pathways
12.34 TLR4 TLR2 IL5 IL4 IL13 IL10
Show member pathways
12.21 TLR2 IL5 IL4 IL13
Show member pathways
12.13 TLR4 TLR2 IL4 IL10
Show member pathways
11.9 TLR4 TLR2 IL5 IL13
8 11.84 IL5 IL4 IL10 CD4
9 11.8 TLR4 TLR2 IL10
10 11.78 IL5 IL4 CD4
Show member pathways
11.78 TLR4 TLR2 IL10 CD4
Show member pathways
11.69 TLR4 TLR2 IL4 CD4
13 11.67 IL5 IL4 IL13
14 11.54 IL5 IL4 IL13
15 11.53 IL5 IL4 IL10
16 11.46 IL5 IL4 IL13 IL10 CD4
17 11.41 TLR4 TLR2 IL10
18 11.39 IL4 IL13 IL10
19 11.18 IL5 IL4 IL13
20 11.04 IL5 IL4 IL13 IL10
21 11.02 IL5 IL4 IL13 IL10 CD4
22 10.62 IL5 IL4 IL13
23 10.48 IL5 IL4 IL13 IL10 CD4

GO Terms for Filarial Elephantiasis

Biological processes related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.89 IL5 IL4 IL13 IL10 CD4
2 response to lipopolysaccharide GO:0032496 9.85 TLR4 TLR2 IL13 IL10
3 negative regulation of endothelial cell apoptotic process GO:2000352 9.7 IL4 IL13 IL10
4 microglial cell activation GO:0001774 9.65 TLR2 IL4 IL13
5 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.61 TLR4 TLR2
6 I-kappaB phosphorylation GO:0007252 9.61 TLR4 TLR2
7 positive regulation of interleukin-10 secretion GO:2001181 9.6 IL4 IL13
8 positive regulation of mast cell degranulation GO:0043306 9.59 IL4 IL13
9 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.58 IL4 IL10
10 response to molecule of bacterial origin GO:0002237 9.58 TLR2 IL10
11 cellular response to lipoteichoic acid GO:0071223 9.57 TLR4 TLR2
12 type 2 immune response GO:0042092 9.56 IL4 IL10
13 regulation of isotype switching GO:0045191 9.54 IL4 IL10
14 positive regulation of interleukin-10 production GO:0032733 9.54 TLR4 TLR2 IL4
15 negative regulation of complement-dependent cytotoxicity GO:1903660 9.51 IL4 IL13
16 positive regulation of macrophage activation GO:0043032 9.5 TLR4 IL13 IL10
17 immune response GO:0006955 9.5 TLR4 TLR2 IL5 IL4 IL13 IL10
18 positive regulation of matrix metallopeptidase secretion GO:1904466 9.46 TLR4 TLR2
19 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.43 TLR4 TLR2
20 macrophage activation GO:0042116 9.43 TLR4 IL4 IL13
21 asparaginyl-tRNA aminoacylation GO:0006421 9.4 NARS2 NARS1
22 positive regulation of MHC class II biosynthetic process GO:0045348 9.33 TLR4 IL4 IL10
23 positive regulation of B cell proliferation GO:0030890 8.92 TLR4 IL5 IL4 IL13

Molecular functions related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 IL5 IL4 IL13 IL10
2 growth factor activity GO:0008083 9.26 IL5 IL4 IL10 EPGN
3 lipopolysaccharide receptor activity GO:0001875 9.16 TLR4 TLR2
4 asparagine-tRNA ligase activity GO:0004816 8.62 NARS2 NARS1

Sources for Filarial Elephantiasis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....